A phase III, multicentre, randomized, open label clinical trial comparing azacytidine (Vidaza) versus fludarabine and cytarabine (Fluga Scheme) in elderly patients with newly diagnosed acute myeloid leukemia.

Trial Profile

A phase III, multicentre, randomized, open label clinical trial comparing azacytidine (Vidaza) versus fludarabine and cytarabine (Fluga Scheme) in elderly patients with newly diagnosed acute myeloid leukemia.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2016

At a glance

  • Drugs Azacitidine (Primary) ; Cytarabine; Cytarabine; Fludarabine; Fludarabine
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms FLUGAZA
  • Most Recent Events

    • 08 Dec 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017.
    • 06 Dec 2016 Preplanned interim safety analysis result (n=162, date cut of from Oct 2014 to Apr 2016) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 13 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top